Inland Empire Liver Foundation

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)3 trials
• Crohn's disease2 trials
• Liver and biliary tract cancer2 trials
• Obesity2 trials
• High blood pressure1 trial
• Liver cirrhosis1 trial
• Type 2 diabetes1 trial
• Ulcerative colitis1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 2/32 trials
• Phase 11 trial
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Not yet recruiting1 trial
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Amgen2 trials
• Blueprint Medicines Corporation1 trial
• CStone Pharmaceuticals1 trial
• Galectin Therapeutics Inc.1 trial
• HighTide Therapeutics (Hong Kong) Limited1 trial
• and 3 more

Running trials

• Recruiting

  Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

  NCT07848191· Phase 4· Madrigal Pharmaceuticals, Inc.· Source

  Contact: Tom Hare

• Recruiting

  Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Phase 3· Amgen· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

  NCT07441252· Phase 2· Amgen· Source

• Active, not recruiting

  A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

  NCT04194775· Phase 3· CStone Pharmaceuticals· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

  NCT05623189· Phase 2· HighTide Therapeutics (Hong Kong) Limited· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Phase 2/3· Galectin Therapeutics Inc.· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source

• Completed

  A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

  NCT02508467· Phase 1· Blueprint Medicines Corporation· Source